FDA rejects Portola's anticoagulant antidote AndexXa
The US Food and Drug Administration has turned down approval of Portola Pharmaceuticals’ (Nasdaq: PTLA) anticoagulant antidote product for the time being, sending the company’s shares down 11% to $23.69 in regular trading on Wednesday, and the stock was 17.7% lower at $19.50 in pre-market trading today.
The FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for AndexXa (andexanet alfa).
An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, Bristol-Myers and Pfizer’s Eliquis, rivaroxaban, Bayer’s Xarelto, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze